Financials
Financial year 2026
LELIMA PHARMA from Ottignies-Louvain-la-Neuve, company number BE0691649590, closed financial year 2026 with a result of € 54,519 after tax. For that financial year LELIMA PHARMA recorded a gross margin of € 70,644 and equity of € 247,899. Compared with financial year 2025, the result moved from € 45,404 to € 54,519. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 21, 2026.
€ 247,899
▲ 28% vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 54,519
▲ 20% vs 2025
Profit after tax over the fiscal year.
€ 142,665
▲ 45% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € 229,299.
People and assets in 2026
€ 1,334
▼ 67% vs 2025
Book value of vehicles, furniture and equipment.
Debts at end 2026
€ 934,673
▲ € 932,036 vs 2025
€ 73,933 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.
€ 108,186
▲ € 105,536 vs 2025
Supplier invoices still open on the last day of the fiscal year.
€ 3,294
▼ 60% vs 2025
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Gross margin | € 64,050 | € 63,405 | € 58,622 | € 70,644 | ▲ 21% |
| Profit after taxes | € 44,006 | € 45,392 | € 45,404 | € 54,519 | ▲ 20% |
| Equity | € 102,584 | € 147,976 | € 193,380 | € 247,899 | ▲ 28% |
| Total debts | € 17,075 | € 25,189 | € 13,459 | € 1,046,154 | ▲ € 1 million |
| Cash | € 73,405 | € 92,379 | € 98,277 | € 142,665 | ▲ 45% |
| Retained profit | € 83,984 | € 129,376 | € 174,780 | € 229,299 | ▲ 31% |
| Bank debt | € 60 | € 6,814 | € 2,638 | € 934,673 | ▲ € 932,036 |
| Balance sheet total | € 119,659 | € 173,165 | € 206,839 | € 1,294,053 | ▲ € 1.1 million |
By gross margin, LELIMA PHARMA ranks 20th of 41 companies with main activity “Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies” in Ottignies-Louvain-la-Neuve that publish figures (fiscal year 2026).
Key figures of LELIMA PHARMA, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
Ask about LELIMA PHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to LELIMA PHARMA?
What happened at LELIMA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 54,519 (▲ 20% vs 2025). Source: NBB ↗
- CEDRIC MEEUW became a director. NBB
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Ottignies-Louvain-la-Neuve. KBO
In short
From € 44,006 profit in 2023 to € 54,519 profit in 2026.
Paid € 51,353 in corporate taxes since 2023.
Best year ever: 2026, with € 54,519 profit.
Management
Behind LELIMA PHARMA is CEDRIC MEEUW. It owns 100% of PHARDUP SA itself.
Directors
According to the 2026 annual accounts
CEDRIC MEEUW
Director
since 2020
Establishments
Establishment units
Physical locations of this company
Rue Croix Thomas 6
1341 Ottignies-Louvain-la-Neuve
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Ottignies-Louvain-la-Neuve
Same main activity (Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies), 44 active companies in Ottignies-Louvain-la-Neuve, largest first.
€ 706,167 gross margin · 2025
€ 494,250 gross margin · 2025
€ 367,522 gross margin · 2025
€ 264,583 gross margin · 2025
€ 223,496 gross margin · 2025
€ 216,646 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- Cédric MEEUW(oprichter) 99.5%
- Julie HAINE(oprichter) 0.5%
Details
- Company number
- 0691.649.590
- VAT number
- BE 0691.649.590
- Registered office
- Rue Croix Thomas 6, 1341 Ottignies-Louvain-la-Neuve
- Names & denominations
- LELIMA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 March 2018
- Peppol
- Active · Active since 26 Nov 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering